Europe · Regional markets · L'Agefi Suisse

Idorsia obtient le statut de «percée thérapeutique» de la FDA pour Quviviq en pédiatrie

Published by L'Agefi Suisse · Switzerland 13 h ago

Ce statut concerne les patients dès dix ans et vise à accélérer le développement du somnifère. L’étude clinique pivot ne doit toutefois débuter qu’au second semestre de l’an…

Read the full article on L'Agefi Suisse Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (agefi.com)

Also worth reading

This is Money

One of Britain's top female executives to scoop millions as new boss of US tech giant

City A.M.

OBR warns Healey: Stealth taxes to blame for living standards slump

Investors Chronicle

US election results send shares higher

Finews

Private bank appoints branch manager, client advisor and South Africa specialist

MoneyWeek

China is a technology powerhouse: how can you gain exposure?

Maddyness